Competitive analysis
Antibody drug conjugate or bispecific antibody are similar technologies to MINC platform. MINC is superior to to them in delivering drugs to the brain, reducing toxicity and enabling tissue regeneration.
Principles of Suntec’s MINC platform
Flavonoids – Main active ingredients in MINC platform
cancers, neural diseases, autoimmune and cardiovascular). EGCG
(epigallocatechin-3-gallate) is the most biologically active species of the
flavonoid family. There are 4000+ scientific literatures report the functions of EGCG in
disease modulations.
The challenges to use flavonoid as a drug is its instability and low
bioavailability. MINC technology overcomes these challenges.
MINC technology
MINC technology consists of two stable EGCG derivatives, OE and PE, which
fully retain the EGCG functions in disease modulation. OE/PE can form a stable
nanocomplex with selected synergistic drug molecule and function as
combination therapy to modulate multiple signaling pathways of a disease to
reach high total efficacy and response rates. MINC works especially well with
proteins(cytokines/antibodies), genes (RNA/DNA) as well as small chemical
drugs.
MINC is tailored to Proteins and RNA/DNA therapies
MINC does not change the molecular structures or bioactivities of the
encapsulated proteins or genes. These biologics are released in their original
bioactivities.
MINC preserves structure/efficacy of encapsulated Protein drugs
MINC-trastuzumab was used as an example of no change in drug structure after dissociated from MINC nanocomplex (examined by CD spectra)
New Drug Platforms Comparisons:
MINC has more clinical benefits than ADC, Bispecific Ab, and other drug platforms
MINC delivers more drugs to the brain
diseases inclduing glioma and Alzheimer’s disease.
MINC delivers more drugs to tumors
and retention) effect. MINC-trastuzumab is used as an example to show high
drug accumulation in tumor than trastuzumab alone.
MINC reduces drug toxicity (small compounds)
MINC-sunitinib is less toxic with higher efficacy than sunitinib alone.
doxorubicin is toxic at 10 mg/kg and MINC-doxorubicin shows no toxicity at
50 mg/kg.
MINC reduces drug toxicity (protein drugs)
removes the toxicity of anti-CD3 (less body weight reduction and no mouse
death).
MINC improves overall therapeutic efficacy
MINC Applications
For neurodegenerative diseases — MINC targets multiple Alzheimer’s disease pathways as an effecitve treatment
Alzheimer’s disease.
OEGCG (OE) and PEG-EGCG (PE) are made from EGCG, which is well documented
in treating Alzheimer’s disease, targeting multiple stages at disease
progression. Suntec is developing multiple AD pipeline drugs based on MINC
platform now.
For brain cancer — MINC ingredients are effective in overcoming multiple glioma resistant
signaling
resistant cancers. Our data suggest that MINC ingredient OEGCG is effective in treating
both temozolomide sensitive and resistant gliomas. The underlie
mechanisms are also well documented by EGCG. Suntec is developing
multiple pipeline drugs for glioma and broader cancer types using MINC
platform now.
For RNA drugs — MINC ingredients are effective in preventing RNA degradation
For vaccine, EGCG can also induce higher antibody titer.
MINC overcomes clinical problems
